JAK1 and melanoma: In addition, deletion of genes necessary for IFN-γ signaling (such as IFNGR1, IFNGR2, STAT1, JAK1, and JAK2) have been noted in pre-clinical models of melanoma that can lead to resistance to anti-PD-1/PD-L1 therapies, which might also play a role in acquired resistance [31].